Page last updated: 2024-11-05

naphthoresorcinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Naphthoresorcinol, also known as 1,3-dihydroxynaphthalene, is a polycyclic aromatic compound with potential applications in organic synthesis and materials science. It is a white solid that is sparingly soluble in water but soluble in organic solvents. Naphthoresorcinol can be synthesized through various methods, including the reduction of 1,3-dinitrobenzene or the reaction of 1,3-dihydroxybenzene with phthalic anhydride. Naphthoresorcinol exhibits diverse biological activities, including antioxidant, anti-inflammatory, and antimicrobial properties, which have sparked interest in its potential therapeutic applications. Its fluorescent properties make it a valuable reagent for fluorescent probes and chemosensors. Research on naphthoresorcinol focuses on exploring its synthesis, biological activities, and potential applications in various fields, including pharmaceuticals, materials science, and environmental monitoring.'

naphthoresorcinol: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8601
CHEMBL ID381547
SCHEMBL ID28681
MeSH IDM0088186

Synonyms (50)

Synonym
AC-15068
ai3-08780
ccris 7896
nsc 115890
1,3-naphthalenediol (8ci,9ci)
naphthoresoucinol
einecs 205-079-7
brn 2044002
naphthoresorcinol
nsc-115890
3-hydroxybenzocyclohexadien-1-one
132-86-5
1,3-naphthalenediol
wln: l66j bq dq
1,3-dihydroxynaphthalene
nsc115890
naphthalene-1,3-diol
1,3-dihydroxynaphthalene, >=99%, crystalline
bdbm23449
inchi=1/c10h8o2/c11-8-5-7-3-1-2-4-9(7)10(12)6-8/h1-6,11-12
N-2150
D0588
AKOS005145943
CHEMBL381547
A806508
unii-5x457yew8y
4-06-00-06543 (beilstein handbook reference)
5x457yew8y ,
FT-0631769
S10388
1,3-dihydroxy-naphthalene
2,4-dihydroxynaphthalene
SCHEMBL28681
naphthoresorcinol [mi]
DTXSID8059631
naphthoresorcin
naphthalenediol-(1,3)
STL416210
mfcd00003965
1,3-dihydroxynaphthalene, for spectrophotometric det. of glucuronic acid according to tollens, >=97.0%
SY010964
DS-14529
1-hydroxy-3-naphthol
6-methoxypyridine-2-carboxylicacidamide
LCZC2960
AMY6315
Q27262989
CS-0010073
1,3-naphthalindiol
HY-D0165
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)IC50 (µMol)3.30000.00271.62879.9000AID540067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
quinone catabolic processRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
dihydronicotinamide riboside quinone reductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
zinc ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
electron transfer activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donorsRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
chloride ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein homodimerization activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
FAD bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
melatonin bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
resveratrol bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleoplasmRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
extracellular exosomeRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID540067Inhibition of human recombinant NQO22010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
AID261691Antiproliferative activity against human bladder carcinoma T24 cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Selective antiproliferative activity of hydroxynaphthyl-beta-D-xylosides.
AID261690Antiproliferative activity against human fibroblast HFL1 cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Selective antiproliferative activity of hydroxynaphthyl-beta-D-xylosides.
AID540069Inhibition of human recombinant NQO2 at 100 uM2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (70.59)18.7374
1990's0 (0.00)18.2507
2000's4 (23.53)29.6817
2010's1 (5.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.89 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]